CFO Tribune

CFO interim

MapLight Therapeutics, Inc. names Jonathan Gillis interim CFO

MapLight Therapeutics, Inc. reported in a Form 8-K filed June 18, 2026 that Jonathan Gillis was named interim interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.

In the filing's words

In connection with the separation of Mr. Setia, the board of directors of the Company appointed Jonathan Gillis, the Company’s Chief Administrative and Accounting Officer, as the Company’s interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.

Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.

CompanyMapLight Therapeutics, Inc. (MPLT)
EventInterim
IncomingJonathan Gillis
OutgoingVishwas Setia
Title in the filinginterim Chief Financial Officer and interim principal financial officer
EffectiveJune 18, 2026
8-K filedJune 18, 2026
Internal promotionNot established by the source
SEC CIK0001770069

MapLight Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed June 18, 2026. The filing's own words are quoted above.

Sources

  • sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26

Something wrong about Jonathan Gillis? Send a correction with the primary source.